Weight loss drug Qnexa wins support of FDA advisory panel

Qnexa, Vivus

Weight loss drug, Qnexa won strong recommendation from the Food and Drug Administration (FDA) advisory panel despite being potentially risky for heart and birth related issues. The FDA is expected to make its decision in April.

According to the developer:

“Qnexa [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 Diabetes and obstructive sleep apnea. Qnexa is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior.”